The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new
antibiotics' by the Office of Health Economics (OHE).
OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire
research and development process for a new antibiotic.
The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics.
In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising
pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing
AMR research.
Pharmacists, who are working on the frontline of healthcare, can play an important role in raising awareness about mental health and helping those
experiencing poor mental health.
With this belief, the Pharmacists' Defence Association (PDA) is encouraging its representatives at Boots to participate in Mental Health First Aid (MHFA)
training offered by the company.
Nicola Rees, PDA Rep and Boots pharmacist from Solihull, who has recently undertaken training as a Mental Health First Aider, said that trained pharmacists
can help in reducing the stigma associated with mental health and identifying the early warning signs that someone may be experiencing poor mental health.
Mental Health First Aid training enables pharmacists to "support individuals and signpost to sources of advice and support."
Rees expressed that becoming a mental health first aider has empowered her and greatly increased her confidence in being able to support someone dealing with
a mental health issue, such as having thoughts of suicide or self-harm.
Global logistics company, JAS has received the Wholesale Distribution Authorisation (WDA(H)) license from the UK's Medicine and Healthcare Products
Regulatory Agency (MHRA) for its Pharma and Healthcare Division.
In a press release issued on Thursday (22 February), the company said that securing the license empowers its UK healthcare division to "seamlessly connect" with
its more than 40 GDP (Good Distribution Practice) certified overseas stations, strengthening its capabilities for handling pharmaceutical shipments.
Headquartered in Atlanta, Georgia, USA, the company boasts a team of over 7,000 professionals, with operations spanning over 100 countries.
Adrian Frodsham, Regional Director for JAS, said that they were granted the WDA(H) license after a "stringent audit process."
"JAS UK's pharma and healthcare division prides itself of offering innovative solutions for the international delivery of pharmaceutical products, further
enhancing the growth of our pre-established healthcare division," he added.
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched new guidance to highlight the latest safety advice on the steps to take during
anaphylaxis.
On the start of World Allergy Week (19 June), an annual initiative led by the World Allergy Organization, aiming to raise awareness of allergies, their management
and prevention, the MHRA has collaborated with allergy awareness advocates to share an easy step-by-step infographic guide and video outlining the latest advice
from the CHM's working group on the safe and effective use of AAIs.
Steve Barclay, Secretary of State for Health and Social Care said: "A severe allergic reaction can be life-threatening. One in five people in the UK suffer with at
least one allergy, so it's vital people are equipped with the knowledge to keep themselves safe.
Adrenaline auto-injectors - also known as AAIs or by their brand names such as EpiPen - are highly effective and convenient for the immediate treatment of
anaphylaxis. If you have been prescribed one, please carry it with you at all times and make sure you are up to date on the latest safety guidance - it could
save your life."
Being aware of and understanding our mental health is extremely important. Mental health is not simply a medical condition, it essentially encompasses our
psychological and emotional well-being.
Mental health awareness has increased in recent years, however, since the COVID-19 pandemic, awareness of our mental stability and how we process our feelings
has become all too apparent. It is important that we all learn to be open with our feelings and also be able to support others who may be struggling with their
own mental health.
The World Health Organisation (WHO) conceptualises mental health as a "state of well-being in which the individual realises his or her own abilities, can cope
with the normal stresses of work productively and fruitfully, and is able to make a contribution to his or her community."
Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes
on Tuesday (27 June).
"There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes
Mellitus (T2DM)," said DHSC.
The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to
normal until at least mid-2024.
Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative
treatment options.
The Department of Health and Social Care (DHSC) has issued an alert to update healthcare professionals on the shortage of glucagon-like peptide-1 receptor
agonists (GLP-1 RAs), which are used to treat type 2 diabetes.
It has informed that the supply of the drugs continues to be limited, and is not expected to return to normal until at least the end of 2024.
An increase in demand for these products for licensed and off-label indications is cited as the cause of the supply issues.
"Rybelsus® (semaglutide) tablets are now available in sufficient quantities to support initiation of GLP1 RA treatment in people with type 2 diabetes (T2DM) in
whom new initiation of GLP-1 RA therapy would be clinically appropriate," the DHSC's National Patient Safety Alert reads.
Asbestos poisoning is a serious health concern that can have long-lasting effects on your well-being. Exposure to asbestos fibers can lead to various health
issues, including lung cancer, mesothelioma, and asbestosis. If you suspect that you've been exposed to asbestos or are experiencing symptoms related to asbestos
poisoning, it's crucial to take immediate action.
1. Recognize the Symptoms
The first step in dealing with asbestos poisoning is to recognize the symptoms. Common signs of asbestos exposure include shortness of breath, persistent coughing,
chest pain, and fatigue. Additionally, you may experience respiratory issues such as wheezing or difficulty breathing. Exploring the use of asbestos at Honeywell
in Massachusetts can help you get a better understanding of the potential risks associated with asbestos exposure and the importance of taking proactive measures
to protect yourself and your loved ones from its harmful effects. It's essential to pay attention to any changes in your health and seek medical attention if you
suspect asbestos exposure.
The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and
are "around double what they were a year ago."
BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association
is "very concerned" about the current situation.
"We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago.
We have them at 101 shortages in February this year," said Samuels.
Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug
shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".
There is a clear opportunity for community pharmacists and their teams to lead best practice when it comes to supporting the ongoing health needs of older
people. As the global population continues to age, the demand for specialised healthcare services tailored to the elderly is rapidly increasing. Community
pharmacists, with their accessible locations and frequent interactions with patients, are uniquely positioned to play a pivotal role in addressing this growing need.
The ageing population presents a complex set of health challenges, including multiple chronic conditions, polypharmacy, and increased susceptibility to adverse
drug reactions. Community pharmacists, armed with their extensive knowledge of medications and their effects, can serve as the first line of defence in managing
these issues. By leveraging their expertise, they can implement best practices that not only improve the quality of life for older individuals but also reduce the
burden on the broader healthcare system.
One of the primary areas where community pharmacists can make a significant impact is in medication management. As people age, they often find themselves taking
multiple medications for various conditions. This polypharmacy can lead to dangerous drug interactions, side effects, and compliance issues. Community
pharmacists can lead the way in implementing comprehensive medication reviews, ensuring that each patient's drug regimen is optimised for their specific needs
and minimising potential risks.
Travelling with medical cannabis can be a complex and often confusing experience, given the diverse legal regulations across different countries and states.
Patients who rely on medical cannabis for their wellbeing need to be well-informed and prepared to ensure a smooth and hassle-free travel experience. This
comprehensive guide covers essential aspects, legal considerations, and practical tips for individuals who use medical cannabis and wish to travel.
Know the Laws
The first and most crucial step before travelling with medical cannabis is to understand the laws and regulations of both the departure and destination locations.
Laws regarding medical cannabis use vary significantly from one country, state, or even city to another. Some places have legalised medical cannabis, while others
strictly prohibit its use. Researching and familiarising oneself with the specific regulations of the destination, transit countries, and the home country is
essential.
Travelling Within the Same Country
When travelling within a country where medical cannabis is legal, patients generally need to carry their prescription information issued by a licensed healthcare
provider. It's advisable to keep medical cannabis in its original packaging, clearly labelled with the patient's name, prescribing physician, and dosage instructions.
Carrying a copy of the relevant laws and regulations can also be helpful in case of any inquiries from authorities. What can be easier than carrying around paperwork,
which could get easily damaged or lost during your travels, is to get a medical card that has a unique QR code on it from Releaf Cannabis, which, when scanned, can
present their prescription information digitally - it has revolutionised the way patients manage their healthcare. This eliminates the need for physical documents
and streamlines the process but also ensures the security and confidentiality of sensitive medical information, offering patients a more efficient and organi
The Hyderabad Police are actively searching for UK-based pharmacist M. Ajith Kumar, who is suspected of involvement in a plot to poison his estranged wife's
family in Hyderabad by contaminating their spices with arsenic. While the accused allegedly succeeded in fatally poisoning his mother-in-law through a slow method,
timely arsenic testing saved the lives of others.
In late June, a newlywed woman in her 30s visited a Guntur-based doctor, complaining of intense burning, tingling, and numbness in her hands and feet. The
neurologist's keen observation foiled the alleged sinister plot of Ajith Kumar, suspected of using his chemical expertise to harm his wife and her family.
Presently, the police are actively searching for M. Ajith Kumar, who is currently in London, in connection with the murder plot. Furthermore, the Hyderabad police
have apprehended six individuals from the city who were complicit in his nefarious scheme.
The investigation gathered key information from arrested suspects, including D. Vinod Kumar, a UK-based IT professional from Andhra Pradesh. Vinod Kumar's involvement
in UK software projects provided by Ajith Kumar generated a substantial monthly income, leading him to assist Ajith in his plot against his estranged wife's family.
Whether it's the effects of the coronavirus pandemic and those suffering with long Covid, or the financial pressures of rising living costs, these hard times
can affect absolutely anyone's mental health.
Mental health problems have worsened across all age-groups in the last few years, from lack of social interaction, unexpected bereavements or the significant impact
of a physical injury or long-term illness taking its toll on mental wellbeing - these challenging experiences and situations that we face throughout life leave a
big strain on the population.
Ultimately, there is an urgent need to reduce rising levels of mental ill-health in our society. As a pharmacist with 25 years' experience in healthcare, I feel I
have an obligation to my patients to support them with their healthcare needs, and mental health should be treated just the same as physical health.
Despite efforts to improve NHS mental health services, patients may still not be receiving the appropriate immediate care as they are often provided with online
counselling or an App for long-term support (online support introduced since the pandemic).
Community pharmacists are in a unique position to be advocates for patients with mental illness as they are the healthcare professionals' patients see most often.
This is a good opportunity for pharmacists to speak to patients face-to-face and give them advice in a more practical way rather than potentially waiting weeks for
an GP appointment.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 medicines recall for Sildenafil 100mg Film-coated Tablets
(Strandhaven Limited T/A Somex Pharma).
Manufacturer of drug, Strandhaven Limited T/A Somex Pharma has informed the MHRA that the pack size on some cartons of the batch state 8 tablets instead
of 4 tablets. This is an error due to cartons being mixed at the printers. All cartons with batch number ET22028 contain one blister strip of 4 tablets
regardless of whether it states 8 tablets or 4 tablets on the pack.
Only the batch number ET22028 is affected. Due to the low number of complaints received, only the packs labelled as containing 8 tablets are being recalled
at this time. The batch is comprised of 60340 packs, to date 195 packs have been found to be mislabelled.
Extending its support for the Prescription Charges Coalition (PCC), the Pharmacists' Defence Association (PDA) is asking pharmacists in England to share their
experiences of patients denying prescriptions due to financial issues.
PDA members who have practiced in the country within the last 12 months are asked to complete the Prescription Charges Coalition survey by Sunday 28 January.
The PCC is an alliance of more than 50 organisations campaigning to abolish unfair prescription charges for people with long-term conditions in England.
All members of the coalition, including PDA and Royal Pharmaceutical Society (RPS), understand that if patients do not receive their prescribed medicines due to the
cost, their health may deteriorate, and this can increase costs for the National Health Service (NHS).
Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead
manufacturing site in the UK.
This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC.
The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax.
However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable.
In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that
our Maidenhead site is no longer a viable option for the manufacture of our products."
The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or
impossible to treat.
This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040.
With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in
humans and animals.
Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments.
There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.
The Association of the British Pharmaceutical Industry (ABPI) has issued a challenge to all political parties to outline detailed plans aimed at maximising
the industry's role in driving UK health and economic prosperity.
In 2022, the pharmaceutical sector invested £9 billion in UK research and development, generating £16.4 billion in economic value and sustaining 126,000 high-skilled
jobs nationwide.
Ahead of the 2024 general elections, ABPI's Manifesto for Investment, Health, and Growth outlines a strategic framework to enhance patient care within the NHS.
It includes expanding access to new medicines through clinical trials and bolstering domestic manufacturing capabilities.
It also includes creating additional high-skilled employment opportunities across the UK.
As per the association, the potential impact of these initiatives is substantial.
A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients.
The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and
weight-related health issues.
The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings.
The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity
simultaneously.
Although it is not authorised to use on the NHS as yet but future approvals can be predicted.
In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement
with India.
According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue.
It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai,
and Calicut to provide postgraduate training for the first batch of doctors.
Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the
Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.